yohimbine has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colau, D; Dolusić, E; Frédérick, R; Larrieu, P; Masereel, B; Moineaux, L; Pilotte, L; Pochet, L; Stroobant, V; Van den Eynde, B; Wouters, J | 1 |
| Huigens, RW; Luesch, H; Norwood, VM; Paciaroni, NG; Ratnayake, R | 1 |
2 other study(ies) available for yohimbine and Neoplasms
| Article | Year |
|---|---|
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line; Drug Design; Enzyme Inhibitors; Humans; Immunologic Factors; Indoles; Kinetics; Mice; Neoplasms; Structure-Activity Relationship; Tryptophan Oxygenase | 2011 |
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
Topics: Antineoplastic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Molecular Targeted Therapy; Neoplasms; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Yohimbine | 2020 |